Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Go back to Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform| Tempest Trading Technologies, Inc. (NASDAQ: TPST) | Delayed: 0.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.77 | 52 Week High | $0.01 | |||
| Open | $0.77 | 52 Week Low | $0.00 | |||
| Day High | $0.77 | P/E | N/A | |||
| Day Low | $0.77 | EPS | $0.00 | |||
| Volume | 72,069 | |||||
